| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2008: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Research Abstract |
Targeted alpha therapy (TAT) has been applied for cancer therapy and many clinical studies have been performed. Uranium-230 is a promising cyclotron produced alpha-emitting radionuclide for TAT. According to the reaction ^<232>Th(p, 3n)^<230>Pa and following the β- decay of ^<230>Pa, ^<230>U can be produced within the irradiated target. The daughter of ^<230>U, ^<226>Th (T_<1/2>=31m) provides a rapid cascade of 4 alpha particles with a 27.7MeV of total energy. In this study, we investigated the availability of production and radiochemical separation of ^<230>U and its daughters. Protactinium-230 was produced by irradiation of ^<232>ThO_2 target. After irradiation, the target was separated and ^<230>U/^<226>Th generator was constructed. Eluted ^<226>Th from generator was radiolabeled with bone seeking chelate, EDTMP and injected into mice for biodistribution evaluation. Most of all radioactivity were retained on bone.
|
